| abstract |
Disclosed herein are compounds that form covalent bonds with Bruton-type tyrosine kinases (Btk). Similarly, reversible inhibitors of Btk are also described. In addition, irreversible inhibitors of Btk are also described. Further disclosed are pharmaceutical compositions comprising the compounds. Btk inhibitors are used alone or in combination with other therapeutic agents to treat autoimmune diseases or conditions, heterogeneous immune diseases or conditions, cancers including lymphoma, and inflammatory diseases or conditions A method is disclosed. [Selection figure] None |